交流互鉴促提升，经验共享谋发展 此次交叉督查不仅是工作检验，更是宝贵的经验交流。在座谈会上，一线执法人员围绕监管难点、社会 共治、案件裁量等共性问题进行深入探讨，共收集经验做法、社会共治、问题建议等7条，为提升化妆 品监管能力建设真诚交换意见、共谋思路方法。此外，聚焦实操性与精细度，研讨多头执法难题，精准 把脉进口免税化妆品监管痛点。 丰台区市场监管局亮出守护用妆安全"特色牌"：以"以案释法、条款解读、风险提示"三位一体的药品安 全法治宣传教育基地为载体，构建了沉浸式普法新格局；打造"美丽丰行"服务品牌，与区生物医药健康 专班、园区"先丰港"、北京日化协会等多部门形成合力，推动辖区首家化妆品新原料企业取得备案、化 妆品功效检测企业获得认证、化妆品生产企业迁入丰台，形成辖区化妆品全产业链体系。 中国质量新闻网讯 为全面检验2025年辖区化妆品经营环节监管效能，在北京市药监局统一部署下，北 京市丰台区市场监管局联合海淀区、石景山区、门头沟区市场监管局及市药监局相关单位，组建京西地 区"美丽卫士"团队，开展化妆品经营环节交叉督导检查，共筑用妆安全防线。 聚焦重点强督查，压实责任筑防线 本次交叉督查严格对标市药监局工 ...

经济观察网 国家药监局2月5日发布通告，2025年国家化妆品抽样检验工作中，经贵州省食品药品检验 所等单位检验，产品标签标示名称为俏因子草本清肌泥膜粉等50批次化妆品不符合规定。 根据《化妆品监督管理条例》《化妆品生产经营监督管理办法》《化妆品抽样检验管理办法》，国家药 品监督管理局已要求浙江、广东、青海省药品监督管理部门对上述不符合规定化妆品涉及的注册人、备 案人、受托生产企业等依法立案调查，责令相关企业依法采取风险控制措施并开展自查整改。各省级药 品监督管理部门要依法责令相关化妆品经营者停止经营上述化妆品，并依法调查其进货查验记录等情 况，对违法产品进行追根溯源，发现违法行为的，依法严肃查处；涉嫌犯罪的，依法移送公安机关。 ...

子长市市场监督管理局 处罚日期 2025年12月30日 子市监处罚〔2025〕61号 浏览：2次 基本信息： 处罚机关 处罚依据 《化妆品监督管理条例》 / 第六十条 / 第五项 变更： 文本信息：该行政处罚决定未上传处罚文书。 处罚种类 没收非法财物,警告,罚款 ...

除了生产端，销售端的线上渠道特性也让监管难度进一步升级。当前化妆品销售越来越以线上渠道为主 阵地，直播等网络销售涉及多个环节主体、隐秘性强，有些环节很难在监管层面被发现。"线上销售的 产品经营地、注册地、发货地、生产地均不相同，主体多元、复杂。直播销售的广告话术、链接产品均 为即时动态更新，监管很难把控。"该负责人表示。 除上述具体难点外，监管资源与任务量存在不匹配的长期矛盾，也是制约监管效能的关键因素。尽管法 规标准体系日趋完善，但如何更科学、高效地实施监管，仍是重大课题。 为破解监管困境，2025年11月，国家药品监督管理局发布了《关于深化化妆品监管改革促进产业高质量 发展的意见》（下称《意见》），该《意见》被业内人士称为"24条"。 12月30日，在第二届丽水市生态美妆产业发展大会上，化妆品行业相关监管部门负责人表示，国内化妆 品行业发展迅速，但受产品安全使用风险突出、线上销售环节不透明，加之生产源头管控薄弱等因素影 响，行业监管仍面临不少现实难度。 "该份文件是在2020年《化妆品监督管理条例》基础上的一次重大革新，融入了我们五年来总结的基本 经验，其中最难的是论证环节"。前述负责人告诉经济观察报，文 ...

Core Viewpoint - The Yunnan Provincial Drug Administration has published five typical cases to strengthen the supervision of drug safety and combat illegal activities related to drugs, cosmetics, and medical devices, ensuring public health and safety. Group 1: Case Summaries - Case 1: A pharmacy in Changning purchased drugs from unqualified individuals, leading to the confiscation of illegal drugs and a fine totaling 250,000.00 yuan for the illegal purchase of drugs valued at 33,252.00 yuan [2][3] - Case 2: A gang led by Jiang Mouyan was involved in the production and sale of counterfeit drugs, resulting in the seizure of over 1.1 million suspected counterfeit drugs and a total case value exceeding 50 million yuan. The main offenders received prison sentences ranging from 1 year to 11 years and fines totaling 233,000 yuan [4][5] - Case 3: A traditional Chinese medicine clinic in Gejiu used expired drugs, leading to a fine of 20,000.00 yuan and the confiscation of expired drugs valued at 942.85 yuan [6][7][8] - Case 4: A hospital in Wenshan prepared traditional Chinese medicine without the necessary license, resulting in the confiscation of 381 bags of unlicensed medicine and a fine based on illegal gains of 28,600.00 yuan [9][10] - Case 5: A hair product store in Shangri-La sold unregistered cosmetics and failed to maintain proper purchase records, leading to a total fine of 5,105.00 yuan and the confiscation of 13 bottles of cosmetics [11][12]

Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) held a meeting to summarize the regulatory achievements of 2025 and discuss key work for 2026, emphasizing the need for comprehensive regulatory reforms in the cosmetics industry [1] - The meeting highlighted that the Chinese cosmetics market is projected to reach a total transaction value of 1,073.82 billion yuan in 2024, indicating continuous market expansion [1] - Despite the growth, the industry faces structural issues, with over 20,000 registered cosmetics companies but low market concentration and a lack of globally influential brands [1] Group 2: Clinical Innovations and Approvals - The first non-injection epinephrine product, Neffy® (优敏速®), has been approved in China for emergency treatment of severe allergic reactions, marking a significant milestone in drug innovation [4] - HaiXiang Pharmaceutical announced the initiation of Phase II clinical trials for NWRD06, a novel nucleic acid drug aimed at preventing liver cancer recurrence, which is the first of its kind targeting the GPC3 marker [5] - Xinhua Medical received registration for two types of medical devices, enhancing its competitiveness in the in vitro diagnostics market [6] Group 3: Financing and Market Expansion - Beijing Ruifeng Biotechnology completed a C-round financing of over 100 million yuan, aimed at expanding its commercial capabilities and enhancing research and development in both human and animal health [8][9] - Humatrix Medical announced the completion of an A+ round financing of over 100 million yuan, which will be used to advance clinical trials for its core product and expand its product pipeline [10] Group 4: Healthcare Insurance and Spending - The National Healthcare Security Administration reported that from January to November 2025, the total income of the basic medical insurance fund reached 2.632 trillion yuan, with total expenditures of 2.110 trillion yuan, indicating stable fund operations [12]

人民财讯12月29日电，12月29日，国家药监局在石家庄召开化妆品监管工作座谈会，总结2025年监管工 作成效，分析当前形势，研究2026年重点工作思路。会议强调，2026年是"十五五"规划开局之年，要深 入贯彻落实党的二十大和二十届历次全会精神，按照国家药监局的统一部署，围绕中心、突出重点，持 续深化全过程监管改革，全方位筑牢安全底线，全链条促进化妆品产业高质量发展。 ...

Core Viewpoint - The company, Han Shu, has publicly responded to concerns regarding the presence of epidermal growth factor (EGF) in its products, assuring consumers that all its products do not contain EGF [1] Group 1: Company Response - Han Shu issued a statement on its official Weibo account, addressing consumer worries about the "Han Shu Plumping and Firming Essence Mask" and "Han Shu Brightening and Whitening Mask" allegedly containing EGF [1] - The company has initiated a comprehensive self-inspection and traceability process following the reports [1] - In November 2025, the Shanghai Municipal Drug Administration conducted on-site verification and testing of the products, confirming that no EGF was found in the samples tested [1] Group 2: Commitment to Regulations - Han Shu expressed its commitment to adhere strictly to national regulations such as the "Cosmetics Supervision and Administration Regulations" and "Cosmetics Safety Technical Specifications" [1] - The company emphasized its dedication to continuous improvement of products and services, aiming to maintain consumer trust and expectations [1]

Group 1 - The core viewpoint emphasizes the importance of enhancing cosmetic regulation to ensure public safety and effectiveness in monitoring [1] - The Shandong Provincial Drug Administration is implementing a targeted sampling inspection plan for cosmetics in 2025, focusing on children's cosmetics, special cosmetics, and products with high non-compliance rates [1] - The sampling process will cover the entire production and sales chain, with increased inspection efforts in key areas such as trading markets and e-commerce platforms to ensure representativeness and problem orientation [1] Group 2 - A strict "five measures in place" principle will be enforced for non-compliant cosmetics, including product control, source tracing, cause investigation, administrative penalties, and corrective actions [2] - Immediate actions will be taken against confirmed non-compliant products, including orders for removal, suspension, and recall, along with legal investigations into the source of issues [2] - A traceability mechanism for non-compliant products will be established, facilitating collaboration with regulatory bodies in other regions to enhance cross-regional regulatory efforts [2]

Core Viewpoint - The article highlights the severe penalties imposed on Nanjing Sucao Tang Pharmaceutical Co., Ltd. for providing falsified cosmetic registration documents, reflecting a strict regulatory stance in the cosmetics industry against such fraudulent practices [1][2][17]. Group 1: Regulatory Actions - Nanjing Sucao Tang was fined a total of over 2.07 million yuan for submitting fake "test reports" and safety assessment documents for 14 cosmetic products [1][4]. - The penalties included a fine of 2,052,345.63 yuan, confiscation of illegal gains amounting to 24,000 yuan, and the cancellation of product registrations for 14 items [4][18]. - The company is barred from submitting related registration applications for three years, indicating a zero-tolerance policy from regulatory authorities towards registration fraud [2][4]. Group 2: Company Background and Violations - Nanjing Sucao Tang, established in 2016, operates in various sectors including medical beauty and personal care, with brands such as Sucao Tang and Suberal [3][4]. - The company has a history of regulatory violations, having been penalized multiple times in the past three years, indicating systemic compliance issues [6][11]. - The specific violations involved the submission of falsified documents, which contravenes the requirements for the authenticity of registration materials as per the Cosmetics Supervision and Administration Regulations [4][17]. Group 3: Industry Implications - The incident underscores a broader trend in the cosmetics industry towards stricter regulatory enforcement, with increasing penalties for violations becoming a norm [17][21]. - Regulatory measures now encompass financial penalties, qualification penalties, and market bans, reflecting a comprehensive approach to compliance enforcement [18][21]. - The article emphasizes the need for companies to establish robust compliance systems to navigate the increasingly stringent regulatory landscape, as any attempts to circumvent regulations will face severe repercussions [17][21].